Improved Balance Sheet Paves Way for Increased Revenue, Potential Uplisting and Stronger Shareholder Value
REDONDO BEACH, CA – (UPTICK Newswire – December 16, 2015) – Pressure BioSciences Inc. (PBIO) has delivered on its promise to shareholders to remove all of the variable rate debt from its balance sheet by the year’s end. In a recent press release, the company announced that it raised an additional $730,000 of its $5 million PIPE, which brings the total capital raised in the financing to $4,755,000. The move clears the way for the Company to begin to concentrate its efforts on increasing its revenue through additions to its currently small sales and marketing team, improving its operating functions, and for a potential uplisting in early 2016 to a national exchange.
Uplisting to a National Exchange
Pressure Bio’s management team has made it clear that they intend to make it a priority in 2016 to relist on a national exchange in an effort to build shareholder value.
“We are looking at the possibility of an uplist at some time next year, when the time is right. We will know when the time is right when we believe the value of the company based on its stock price is fair to shareholders and the market is appropriate,” said CEO Richard Schumacher during the company’s third quarter conference call in November. “Our goal is to eliminate all variable rate debt on our balance sheet on 12/31/15. We think that is going to go a long way to helping us get back on a national exchange, and we believe that getting back on such an exchange will bring value to PBIO.”
The prospect of an uplisting provides a strong catalyst for investors next year. Since many institutional investors are forbidden from investing in over-the-counter stocks, or are deterred from doing so because of massive red tape, the uplisting to a national exchange would open the door to a significant number of additional investors. The Company’s now clean balance sheet and the marketing/sales investments Mr. Schumacher has indicated are coming, could make the stock even more attractive to these investors, especially if the stock is trading at a discount to its peers.
Investing in Sales & Marketing
Pressure Bio plans to spend the rest of its PIPE proceeds on expanding its sales and marketing infrastructure. According to the PIPE’s provisions, the offering can be up to 25% oversubscribed, which could bring in a total of about $1.25 million in additional capital.
“We’ve already started to buff-up our capabilities in sales and marketing, but we’re going to expand this important area much more once the last bit of debt is paid off,” said Mr. Schumacher during the company’s Q3 conference call.
The company has also been in co-marketing discussions with at least one large mass spectrometry manufacturer. Since PCT can be used to break up samples faster and with higher quality than current methods prior to mass spectrometry analysis, a co-marketing agreement with a large, multi-national mass spec instrument provider could provide valuable access to key target markets and existing mass spec customers. There are more than 7,000 labs in the U.S. alone that have at least one mass spectrometer, which equates to an enormous target market that is ripe for the taking.
These future efforts come in addition to the Company’s already strong organic revenue growth seen over the past several quarters, following a number of publications from Key Opinion Leaders (KOLs) from around the world featuring the PCT platform.
“We have brought on new important customers who are using, publishing, and presenting on our PCT technology platform. Others in the field are beginning to hear the good comments and see the great data offered by the KOLs. These researchers are calling us and saying, ‘I’d like to see the PCT system that Dr. so-and-so and so-and-so have been using’, so please send me a quotation for a purchase,” added Mr. Schumacher during the conference call.
Pressure Bio represents a unique opportunity within the biotech industry. While companies like Harvard Biosciences Inc. (HBIO) are focused on sample prep and others like NanoString Technologies Inc. (NSTG) are developing molecular identification technologies, these companies are mostly focused in a specific area of the life sciences. Conversely, Pressure Bio represents a unique and somewhat different investment than these other companies, as its PCT platform is more universal and can help scientists broadly while being applicable to many vertical markets.
In addition to its compelling market opportunity, the company’s razor-razorblade business model generates predictable and recurring revenue over time as new labs are added. These dynamics, especially now that the Company has a balance sheet completely void of variable rate convertible debt, could lead to a higher valuation, and soon, as investors gain more confidence in cash flow projections into the future compared to companies selling one-off instruments and other devices.
For more information, visit the company’s website at www.pressurebiosciences.com.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.